References
- Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death. Novartis AG. (2019). www.novartis.com/news/media-releases/novartis-acquire-medicines-company-usd-97-bn-adding-inclisiran-potentially-transformational-investigational-cholesterol-lowering-therapy-address-leading-global
- Fierce Biotech . With long-term data, Med Co, Alnylam's cholesterol-fighter inclisiran poised for 2019 filing. (2019). www.fiercebiotech.com/biotech/long-term-data-med-co-alnylam-s-cholesterol-fighter-inclisiran-poised-for-2019-filing
- The Medicines Company announces that the ORION-9 Study of inclisiran in HeFH patients showed durable and potent LDL-C lowering with twice-yearly dosing. The Medicines Company. (2019). www.themedicinescompany.com/investor/pr/4152740/
- Bristol-Myers Squibb completes acquisition of celgene, creating a leading biopharma company. Bristol-Myers Squibb. (2019). https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-completes-acquisition-celgene-creating-le
- Amgen completes acquisition of Otezla® (apremilast). Amgen Inc. (2019). www.amgen.com/media/news-releases/2019/11/amgen-completes-acquisition-of-otezla-apremilast/
- Recommended cash offer for consort medical Plc by Recipharm Holdings Limited. Consort Medical plc. (2019). https://otp.tools.investis.com/clients/uk/consort_medical/rns/regulatory-story.aspx?cid=1206&newsid=1345434
- New focus in project portfolio of Gerresheimer subsidiary Sensile. Medical. Gerresheimer AG. (2019). www.gerresheimer.com/en/news-events/corporate-news/show/new-focus-in-project-portfolio-of-gerresheimer-subsidiary-sensile-medical.html
- Schneider A , MuellerP , JordiCet al. Hold the device against the skin: the impact of injection duration on user's force for handheld autoinjectors. Expert Opin Drug Deliv. doi:10.1080/17425247.2020.1704730 (2019) ( Epub ahead of print).
- Ypsomed grows strongly with own products. Ypsomed Holding AG. (2019). www.ypsomed.com/en-GB/news/news-reader-detail-page/ypsomed-grows-strongly-with-own-products.html
- AnxietyUK . Injection phobia and needle phobia A brief guide. (2010). www.cnwl.nhs.uk/wp-content/uploads/Needle-Phobia-Booklet.pdf
- Novoheart to co-develop first of its kind human heart-in-a-jar model of heart failure with AstraZeneca. AstraZeneca plc. (2019). www.novoheart.com/hk/press/detail/54
- Detailed results from Phase III DAPA-HF trial showed Farxiga significantly reduced both the incidence of cardiovascular death and the worsening of heart failure. AstraZeneca plc. (2019). www.astrazeneca.com/media-centre/press-releases/2019/detailed-results-from-phase-iii-dapa-hf-trial-showed-farxiga-significantly-reduced-both-the-incidence-of-cardiovascular-death-and-the-worsening-of-heart-failure-01092019.html
- Halozyme announces HALO-301 Phase III study fails to meet primary endpoint. Halozyme Therapeutics. (2019). www.halozyme.com/investors/news-releases/news-release-details/2019/Halozyme-Announces-HALO-301-Phase-3-Study-Fails-To-Meet-Primary-Endpoint/default.aspx
- Halozyme announces actions to focus strategy on ENHANZE® drug delivery technology. Halozyme Therapeutics. (2019). www.halozyme.com/investors/news-releases/news-release-details/2019/Halozyme-Announces-Actions-To-Focus-Strategy-On-ENHANZE-Drug-Delivery-Technology/default.aspx
- Roche's risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy. F. Hoffmann-La Roche AG. (2019). www.roche.com/media/releases/med-cor-2019-11-11.htm
- FDA grants priority review to Roche's risdiplam for spinal muscular atrophy. F. Hoffmann-La Roche AG. (2019). www.roche.com/media/releases/med-cor-2019-11-25.htm
- Vaccine against Ebola: commission grants first-ever market authorization. the European Commission. (2019). https://ec.europa.eu/commission/presscorner/detail/en/IP_19_6246
- Johnson & Johnson announces submission of European marketing authorisation applications for Janssen's investigational Ebola vaccine regimen. Johnson & Johnson. (2019). www.janssen.com/johnson-johnson-announces-submission-european-marketing-authorisation-applications-janssens
- FDA approves REBLOZYL® (luspatercept-aamt) for the treatment of anemia in adults with beta Thalassemia who require regular red blood cell transfusions. Celgene Corporation. (2019). https://ir.celgene.com/press-releases-archive/press-release-details/2019/FDA-Approves-REBLOZYL-luspatercept-aamt-for-the-Treatment-of-Anemia-in-Adults-With-Beta-Thalassemia-Who-Require-Regular-Red-Blood-Cell-Transfusions/default.aspx
- Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez). Novartis International AG. (2019). www.novartis.com/news/media-releases/sandoz-receives-us-fda-approval-long-acting-oncology-supportive-care-biosimilar-ziextenzo-pegfilgrastim-bmez
- STAT . Biogen's top scientist nearly dares FDA not to approve Alzheimer's drug. (2019). www.statnews.com/2019/11/21/biogen-al-sandrock-alzheimers/
- Tolar M , AbushakraS , SabbaghM. The path forward in Alzheimer's disease therapeutics: reevaluating the amyloid cascade hypothesis. Alzheimers Dement.1–8 doi:10.1016/j.jalz.2019.09.075 (2019) ( Epub ahead of print).
- Berk C , SabbaghMN. Successes and failures for drugs in late-stage development for Alzheimer's disease (published correction appears in Drugs Aging. 31(1), 81 [2014]). Drugs Aging30(10), 783–792 doi:10.1007/s40266-013-0108-6 (2013) ( Epub ahead of print).
- Science Daily . Unique case of disease resistance reveals possible Alzheimer's treatment. (2019). www.sciencedaily.com/releases/2019/11/191104112803.htm
- T3D Therapeutics closes $15M financing to advance Phase II development of T3D-959 in a new approach to treating Alzheimer's disease. T3D Therapeutics, Inc. (2019). www.t3dtherapeutics.com/2019/11/06/t3d-therapeutics-closes-15m-financing-to-advance-phase-2-development-of-t3d-959-in-a-new-approach-to-treating-alzheimers-disease/
- Science Daily . Nanoparticle drug delivery provides pain relief and more effective opioid alternative in animal study. (2019). www.sciencedaily.com/releases/2019/11/191104112916.htm